The combination of intravenous Reolysin and gemcitabine induces reovirus replication and endoplasmic reticular stress in a patient with KRAS-activated pancreatic cancer

BACKGROUND: Activating mutations in RAS are present in the majority of pancreatic cancer cases and represent an ideal therapeutic target. Reolysin is a proprietary formulation of oncolytic reovirus that is currently being evaluated in multiple clinical trials due to its ability to selectively replic...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :BMC Cancer
Главные авторы: Mahalingam, Devalingam, Patel, Sukeshi, Nuovo, Gerard, Gill, George, Selvaggi, Giovanni, Coffey, Matt, Nawrocki, Steffan T.
Формат: Artigo
Язык:Inglês
Опубликовано: BioMed Central 2015
Предметы:
Case Report
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4496814/
https://ncbi.nlm.nih.gov/pubmed/26156229
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-015-1518-0
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы